Maduck Sean, a significant figure at Corcept Therapeutics, has reported multiple stock transactions that could impact investor perceptions and confidence in the company. The transactions, which include both acquisitions and sales of common stock, were disclosed in a recent SEC filing.

Background

Corcept Therapeutics Inc, identified under the Central Index Key (CIK) 0001088856, is a company incorporated in Delaware that operates in the pharmaceutical preparations industry. The company focuses on developing and commercializing drugs to treat serious metabolic and psychiatric disorders. Its fiscal year ends on December 31, and it is publicly traded on the NASDAQ under the ticker symbol CORT.

What the Filing Says

The filing, dated November 4, 2026, outlines several transactions conducted by Maduck Sean. On November 2, 2026, Sean acquired 11,841 shares of common stock at a price of $8.27 per share. On the same day, he also sold 11,841 shares at a weighted average price of $81.4183, with actual sale prices ranging from $81.12 to $82.10 per share. This pattern continued on November 3, 2026, when he acquired an additional 13,159 shares at the same price of $8.27 and sold a total of 13,159 shares at a weighted average price of $82.0198.

Impact

These transactions may affect investor perceptions of Corcept Therapeutics, as they reflect strategic adjustments in ownership by a key executive. The filing also notes that these transactions were made under a 10b5-1 plan, which allows for predetermined stock trades, potentially indicating a planned approach to managing equity stakes. The pharmaceutical preparations industry may experience increased scrutiny as executives navigate their stock holdings.

What's Next

The filing does not say what happens next.